Abstract:Glioblastoma (GBM) is the most common and aggressive primary brain malignancy in adults. Poor outcomes for traditional treatments demand targeted therapies based on identified mechanisms that drive tumor development and sustain its malignancy. Molecular pathology studies have classified GBM into subtypes differing in treatment responses and survival rates. Among these subtypes, the mesenchymal (MES) group is associated with the worst prognosis. The Hippo pathway transcriptional co-activator with PDZ-binding motif (TAZ) is one of the three transcriptional regulators that drive the GBM MES gene expression program. Studies from our lab and others have previously shown that TAZ activation is able to promote GBM MES differentiation and progression. Therefore, finding vulnerabilities of TAZ-driven tumors may help to develop targeted therapeutic methods for MES GBM. In an orthotopic GBM mouse model, we found that TAZ-driven tumors show increased expression of thioredoxin reductase 1 (TrxR1), which is responsible for catalyzing the reduction of thioredoxin and maintaining the cellular redox balance. In searching for the cause of increased expression of TrxR1, we found that glucose deprivation can induce TrxR1 expression, suggesting TrxR1 may be an adaptive mechanism for tumor cells to survive in glucose deprivation conditions. Indeed, either depleting TrxR1 genetically or inhibiting TrxR1 pharmacologically can promote tumor cell death under glucose deprivation. Furthermore, knockout TrxR1 in a TAZ-driven mouse GBM model significantly decelerated tumor progression. Collectively, our studies revealed that inhibition of the Trx redox system under glucose deprivation conditions leads to a synergistic cell death induction in GBM cells, therefore making targeting TrxR1 a potential therapeutic strategy for TAZ-driven MES GBM. Citation Format: Miaolu Tang, Kaitlyn Dirks, Soo Yeon Kim, Jessica Thorpe, Wei Li. Targeting thioredoxin reductase 1 (TrxR1) suppresses TAZ-driven glioblastoma progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2910.

The Overexpression and Nuclear Translocation of Trx-1 During Hypoxia Confers on HepG2 Cells Resistance to DDP, and GL-V9 Reverses the Resistance by Suppressing the Trx-1/Ref-1 Axis.

Hypoxia stabilizes microtubule networks and decreases tumor cell chemosensitivity to anticancer drugs through Egr-1.

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

Endothelial-Specific Expression of Mitochondrial Thioredoxin Promotes Ischemia-Mediated Arteriogenesis and Angiogenesis

Endothelial-specific Expression of Mitochondrial Thioredoxin Improves Endothelial Cell Function and Reduces Atherosclerotic Lesions.

FOXP3 Targets KIF5A to Increase Lactate Production and Promote Docetaxel Resistance in Lung Adenocarcinoma

Redox Status of Thioredoxin-1 (TRX1) Determines the Sensitivity of Human Liver Carcinoma Cells (hepg2) to Arsenic Trioxide-Induced Cell Death

Silencing thioredoxin induces liver cancer cell senescence under hypoxia.

Thioredoxin Activity Confers Resistance Against Oxidative Stress In Tumor-Infiltrating Nk Cells

NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells

Thioredoxin-2 Protects Against Oxygen-Glucose Deprivation/reperfusion Injury by Inhibiting Autophagy and Apoptosis in H9c2 Cardiomyocytes.

Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells

Hypoxia-inducible factor independent down-regulation of thioredoxin-interacting protein in hypoxia

Regulation Of Hypoxia Inducible Factor-1 Alpha Expression By The Alteration Of Redox Status In Hepg2 Cells

Overcome radiation resistance in hypoxic cancer cells by inhibition of glycolysis

Abstract 2910: Targeting thioredoxin reductase 1 (TrxR1) suppresses TAZ-driven glioblastoma progression

Role of Thioredoxin Reductase 1 in Multidrug Resistance Caused by Reactive Oxygen Species-Related Cell Apoptosis in Hepatocellular Carcinoma

TRIP13 Activates Glycolysis to Promote Cell Stemness and Strengthen Doxorubicin Resistance of Colorectal Cancer Cells

Thioredoxin Attenuates Oxidized Low-Density Lipoprotein Induced Oxidative Stress in Human Umbilical Vein Endothelial Cells by Reducing NADPH Oxidase Activity

Radiosensitization of Glioma Cells by TP53-induced Glycolysis and Apoptosis Regulator Knockdown is Dependent on Thioredoxin-1 Nuclear Translocation.

Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway